GeneDx Holdings Debt to Equity Ratio 2020-2025 | WGS
Current and historical debt to equity ratio values for GeneDx Holdings (WGS) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. GeneDx Holdings debt/equity for the three months ending March 31, 2025 was 0.20.
| GeneDx Holdings Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-03-31 | $0.19B | $0.26B | 0.73 |
| 2024-12-31 | $0.17B | $0.25B | 0.71 |
| 2024-09-30 | $0.20B | $0.21B | 1.00 |
| 2024-06-30 | $0.20B | $0.19B | 1.01 |
| 2024-03-31 | $0.19B | $0.21B | 0.90 |
| 2023-12-31 | $0.19B | $0.23B | 0.84 |
| 2023-09-30 | $0.16B | $0.25B | 0.64 |
| 2023-06-30 | $0.18B | $0.30B | 0.61 |
| 2023-03-31 | $0.22B | $0.33B | 0.66 |
| 2022-12-31 | $0.24B | $0.25B | 0.94 |
| 2022-09-30 | $0.27B | $0.56B | 0.48 |
| 2022-06-30 | $0.30B | $0.64B | 0.46 |
| 2022-03-31 | $0.19B | $0.33B | 0.57 |
| 2021-12-31 | $0.17B | $0.39B | 0.43 |
| 2021-09-30 | $0.21B | $0.39B | 0.54 |
| 2021-06-30 | $0.44B | $0.01B | 87.64 |
| 2021-03-31 | $0.44B | $0.01B | 87.74 |
| 2020-12-31 | $0.00B | 0.00 | |
| 2020-09-30 | $0.00B | $0.00B | 0.00 |
| 2019-12-31 | $0.00B | $0.00B | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $1.887B | $0.305B |
| GeneDx Holdings Corp. is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by rare disease data sets. GeneDx Holdings Corp., formerly known as Sema4 Holdings Corp., is based in STAMFORD, Conn. | |||